Annual report [Section 13 and 15(d), not S-K Item 405]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.25.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Product Information [Line Items]    
Net Revenue $ 9,362,022 $ 2,532,499
Total operating loss (8,953,445) (7,973,228)
Non-operating income (expense), net (74,736) 57,210
Net loss before income taxes (9,028,181) (7,916,018)
Income tax expense (11,650) (20,993)
Net loss (9,039,831) (7,937,011)
Diagnostic R&D [Member]    
Product Information [Line Items]    
Net Revenue 8,654 19,442
Total operating loss (1,782,882) (1,724,597)
Laboratory Services [Member]    
Product Information [Line Items]    
Net Revenue 9,353,368 2,513,057
Total operating loss (9,946,452) (3,769,783)
General Corporate Activities [Member]    
Product Information [Line Items]    
Total operating loss $ (6,586,133) $ (5,011,347)